Product Description
JNJ-26483327, a multi-targeted reversible kinase inhibitor, is a new drug in development for treatment of cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00676299)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Heart Cancer|Mouth Cancer|Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CR011881 | P1 |
Completed |
Heart Cancer|Mouth Cancer|Acute Respiratory Distress Syndrome |
None |